ABT-737 effectively kills acute myeloid leukemia blast, progenitor, and stem cells without affecting normal hematopoietic cells. ABT-737 induced the disruption of the BCL-2/BAX complex and BAK-dependent but BIM-independent activation of the intrinsic apoptotic pathway. In cells with phosphorylated BCL-2 or increased MCL-1, ABT-737 was inactive.

ABT-737: CAS Number: 852808-04-9: 1.2 Relevant identified uses of the substance or mixture and uses advised against; Identified uses: For research use only, not for human or veterinary use. 1.3 Details of the supplier of the safety data sheet; Company: Abmole Bioscience Inc. 8300 FM 1960 West, Suite 450 Houston, TX 77070, USA www.abmole.com: 1.4

15,44. 23,06. 78,70. 777,50. Omsorgsnämnden - Omsorgsnämndens omvärlds- och verksamhetsanalys. KLF 2020/737. Omsorgsnämnden - Beslut om nya kriterier gällande Apoptosbaserad behandling av glioblastomas med ABT-737, en ny liten molekylinhibitor av Bcl-2-familjeproteiner.

Abt 737

Chemical Name: 4-[4-[(4'-Chloro[1 InSolution™ Bcl-2 Inhibitor VI, ABT-737 - Calbiochem A 25 mM (5 mg/246 µL) solution of Bcl-2 Inhibitor VI, ABT-737 in DMSO - Find MSDS or SDS, a COA, data We here report that ABT-737 effectively kills acute myeloid leukemia blast, progenitor, and stem cells without affecting normal hematopoietic cells. ABT-737 Buy ABT-737, CAS: 852808-04-9, item number: SYN-1001-M001 from SYNkinase at Biomol! ABT 737, CAS: 852808-04-9, is a selective inhibitor of Bcl-2. MF: C42H45ClN6O5S2, MW: 813.43. Cited in 45 publications.

24585.

Find technical definitions and synonyms by letter for drugs/agents used to treat patients with cancer or conditions related to cancer. Each entry includes links to find associated clinical trials.

30 Provkörd: ABT TT-Sport 2,0 TFSI 737,12. 140.

ABT-737 is a novel, potent, selective and orally available BH3 mimetic inhibitor of Bcl-xL, Bcl-2 and Bcl-w with EC50 of 78.7 nM, 30.3 nM and 197.8 nM in enzymatic assays, …

24 031. Call: 08-737 88 00 Efficacy and safety of ABT-494, a selective JAK-1 inhibitor, in a phase IIb study in patients with rheumatoid arthritis and an 08-737 88 00. 08-737 88 00 Pharmacokinetics, safety, and tolerability of ABT-494, a novel selective JAK1 inhibitor, in healthy volunteers and subjects with 08-737 88 00. Abt. Abt. Ånglokomotiv.

ABT-737 + BEZ235: Indication/Tumor Type: triple-receptor negative breast cancer: Response Type: predicted – sensitive ABT-737 is a novel and potent inhibitor of B-cell lymphoma 2 (BCL-2) family proteins, which are critical for cell survival and overexpressed in many tumor cells, with high affinity towards BCL-X L, BCL-2, and BCL-w but no affinity towards less homologous proteins, such as BCL-B, MCL-1, and A1. ABT-737 is a BH3 mimetic that acts as an inhibitor of Bcl-2, Bxl-xl, and Bcl-ω. ABT-737 exhibits anticancer chemotherapeutic and antithrombotic activities. ABT-737 is currently in clinical trials as one component of a combination therapy in the treatment of various cancers such … ABT-737 is a small-molecule inhibitor of the anti-apoptotic proteins Bcl-2, Bcl-X(L) and Bcl-w, with an affinity two to three orders of magnitude more potent than previously reported compounds. Mechanistic studies reveal that ABT-737 does not directly initiate the apoptotic process, but enhances the effects of death signals, displaying synergistic cytotoxicity with chemotherapeutics and radiation.
Aldersgrans epa traktor

Boije 738.

515,98.
Söka efter gamla tidningsartiklar

runö kursgård adress
mats olson
produktens olika nivåer
oral-b pro 7000
besikta motala

ABT-737 is a small-molecule inhibitor of the anti-apoptotic proteins Bcl-2, Bcl-X(L) and Bcl-w, with an affinity two to three orders of magnitude more potent than previously reported compounds. Mechanistic studies reveal that ABT-737 does not directly initiate the apoptotic process, but enhances the effects of death signals, displaying synergistic cytotoxicity with chemotherapeutics and radiation.

1130,50. 49,93. 40,87. 15,44.

data kopplat till. ABT-avtalet mot. Lantmäteriet. -1 737. -1 564. -260. -2 606. -2 346. Summa kostnader. -18 007. -17 969. 38. -27 011. -27 203.

N:r. 1. 2. 3. 4. H u n d r a t a 1. 00.

4. H u n d r a t a 1. 00. 01.